GKOS
GLAUKOS Corp
NYSE · Healthcare · Medical - Devices · US
$242.48
+33.65%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 690.3M | 507.4M | 383.5M | 314.7M | 282.9M |
| Cost of Revenue | 130.3M | 114.2M | 94.0M | 75.6M | 69.0M |
| Gross Profit | 560.0M | 393.2M | 289.5M | 239.1M | 213.9M |
| Operating Expenses | |||||
| R&D Expense | 187.2M | 150.6M | 136.4M | 138.8M | 123.3M |
| SG&A Expense | 434.6M | 329.3M | 262.8M | 224.1M | 192.9M |
| General & Admin Expense | 75.7M | — | 259.2M | — | — |
| Selling & Marketing Expense | 55.2M | — | 3.6M | — | — |
| Other Expenses | 1.5M | — | 12.5M | 5.0M | (20.0M) |
| Total Operating Expenses | 623.3M | 479.9M | 411.8M | 367.8M | 296.2M |
| Cost and Expenses | 753.6M | 594.2M | 505.8M | 443.4M | 365.2M |
| Operating Income (EBIT) | (63.3M) | (86.7M) | (122.4M) | (128.7M) | (82.3M) |
| Non-Operating | |||||
| Interest Income | 9.7M | 10.7M | 11.1M | 9.2M | 2.4M |
| Interest Expense | 4.8M | 4.6M | 10.0M | 13.6M | 13.7M |
| Net Interest Income | 4.9M | 6.1M | 1.1M | (4.5M) | (11.3M) |
| Other Non-Op Income/Expense | (111.2M) | (106.3M) | (23.2M) | (5.0M) | (16.1M) |
| Non-Operating Income (excl Interest) | 105.9M | 101.7M | 13.2M | (8.6M) | 2.4M |
| EBT (Pre-Tax Income) | (174.5M) | (193.0M) | (145.6M) | (133.7M) | (98.4M) |
| Income Tax Expense | (4.7M) | (5.4M) | 771.0K | 934.0K | 766.0K |
| Bottom Line | |||||
| Net Income | (169.8M) | (187.7M) | (146.4M) | (134.7M) | (99.2M) |
| Earnings from Cont. Ops | (169.8M) | (187.7M) | (146.4M) | (134.7M) | (99.2M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (169.8M) | (187.7M) | (146.4M) | (134.7M) | (99.2M) |
| Per Share | |||||
| Basic EPS | ($2.94) | ($3.28) | ($2.77) | ($2.78) | ($2.09) |
| Diluted EPS | ($2.94) | ($3.28) | ($2.77) | ($2.78) | ($2.09) |
| Revenue Per Share | $11.68 | $8.87 | $7.27 | $6.50 | $5.96 |
| Shares | |||||
| Basic Shares Outstanding | 59.1M | 57.2M | 52.8M | 48.4M | 47.4M |
| Diluted Shares Outstanding | 61.2M | 57.2M | 52.8M | 48.4M | 47.4M |
| Profitability Metrics | |||||
| EBITDA | (124.0M) | (146.1M) | (95.6M) | (82.1M) | (48.8M) |
| D&A | 45.2M | 42.3M | 39.9M | 38.0M | 35.9M |
| EBIT | (169.2M) | (188.4M) | (135.6M) | (120.1M) | (84.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Sep 1, 2026